Elicio Therapeutics Inc

ELTX

Company Profile

  • Business description

    Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

  • Contact

    451 D Street
    5th Floor
    BostonMA02210
    USA

    T: +1 857 209-0050

    https://www.elicio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    26

Stocks News & Analysis

stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,976.4025.00-0.28%
CAC 407,850.43106.021.37%
DAX 4024,240.82198.920.83%
Dow JONES (US)45,010.29507.851.14%
FTSE 1009,061.4937.680.42%
HKSE25,688.87150.800.59%
NASDAQ21,020.02127.330.61%
Nikkei 22541,866.16694.841.69%
NZX 50 Index12,808.8414.780.12%
S&P 5006,358.9149.290.78%
S&P/ASX 2008,707.1030.10-0.34%
SSE Composite Index3,599.4417.140.48%

Market Movers